News
06-05-2012, 02:23 AM
Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting drug lapatinib can slow the spread of cancer cells in individuals with advanced breast cancer who have already tried other chemotherapy medications...
More... (http://www.medicalnewstoday.com/releases/246153.php)
More... (http://www.medicalnewstoday.com/releases/246153.php)